

KFIN/GXP/MAR/2021  
April 5, 2021

Mr. Ajay Nadkarni  
M/s. GlaxoSmithKline Pharmaceuticals Limited  
Dr. Annie Besant Road  
Worli  
Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31, 2021.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2021.

Description of Complaint	Opening Balance as on 01.01.2021	Received during the Period 01.01.2021 to 31.03.2021	Attended/Resolved during the Period 01.01.2021 to 31.03.2021	Pending as on 31.03.2021
Non-receipt of Dividend	NIL	12	12	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	01	01	NIL
SEBI	NIL	08	08	NIL
Stock Exchange	NIL	02	02	NIL
Total	NIL	23	23	NIL

This is for your information and record.

Thanking you,

Yours faithfully  
For KFin Technologies Private Limited



Rajitha Cholleti  
Asst. General Manager

**KFin Technologies Private Limited**

(Formerly known as "Karvy Fintech Private Limited")

**Registered & Corporate Office**

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500082

Ph : +91 40 6716 2222, 7961 1000 | <https://www.kfintech.com> | CIN : U72400TG2017PTC117649